Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European...
October 15, 2025 15:50 ET | Source: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of...
September 23, 2025 08:43 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Principal Investigator Dr. David Putrino Participates in National Long COVID Roundtable Convened by Secretary Robert F. Kennedy Jr.

TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) -- PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated in a national...
September 23, 2025 08:30 ET | Source: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral...
September 19, 2025 15:40 ET | Source: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services...
September 04, 2025 10:32 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen

PridCor reports Long COVID case series: combo of valacyclovir, celecoxib & Paxlovid® shows significant, lasting symptom improvement.
August 11, 2025 13:24 ET | Source: Tevogen Bio Inc

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
June 11, 2025 16:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of...
May 05, 2025 08:00 ET | Source: Posit Science

Study Shows Large Improvements in Long COVID Symptoms and Return to Work

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Researchers at the University of Alabama at Birmingham (UAB) have identified what is believed to be the first intervention found in a randomized...
February 25, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...